ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.210,48
0,58%
S&P 500
5.187,70
0,13%
US Dollar vs BRL
5,0746
0,00%
Bitcoin
62.637,00
0,49%
Brent Oil
82,555
-0,37%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) Notícias

SGMO

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SGMO
DataHoraFonteTítuloCódigoCompanhia
02/05/202417:15Business WireSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
22/04/202417:35Business WireSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)NASDAQ:SGMOSangamo Therapeutics Inc
22/03/202409:05Business WireSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingNASDAQ:SGMOSangamo Therapeutics Inc
13/03/202409:05Business WireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
13/03/202409:01Business WireSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPsNASDAQ:SGMOSangamo Therapeutics Inc
12/03/202419:30Business WireSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
27/02/202419:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
12/02/202410:05Business WireSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
06/02/202418:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
05/02/202420:01Business WireSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileNASDAQ:SGMOSangamo Therapeutics Inc
26/01/202413:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SGMOSangamo Therapeutics Inc
28/11/202318:14Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
01/11/202317:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGMOSangamo Therapeutics Inc
01/11/202317:01Business WireSangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
25/10/202317:15Business WireSangamo Therapeutics Announces Third Quarter 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
24/10/202303:01Business WireSangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)NASDAQ:SGMOSangamo Therapeutics Inc
20/09/202317:15Business WireSangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitNASDAQ:SGMOSangamo Therapeutics Inc
08/08/202317:47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SGMOSangamo Therapeutics Inc
08/08/202317:01Business WireSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
01/08/202317:15Business WireSangamo Therapeutics Announces Second Quarter 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
20/07/202309:05Business WireSangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic EditingNASDAQ:SGMOSangamo Therapeutics Inc
17/07/202309:05Business WireSangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered CapsidsNASDAQ:SGMOSangamo Therapeutics Inc
29/06/202309:05Business WireSangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
26/06/202317:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGMOSangamo Therapeutics Inc
22/05/202309:05Business WireSangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
16/05/202309:00Business WireSangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical OfficerNASDAQ:SGMOSangamo Therapeutics Inc
02/05/202317:30Business WireSangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)NASDAQ:SGMOSangamo Therapeutics Inc
26/04/202320:05Dow Jones NewsStocks to Watch: Meta, Teradyne, United Rentals, Sangamo TherapeuticsNASDAQ:SGMOSangamo Therapeutics Inc
26/04/202318:28Business WireSangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
26/04/202318:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGMOSangamo Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SGMO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
VVEO3
CM Hospitalar ON
BOV
CRFB3
CARREFOUR ON
BOV
ETER3
ETERNIT ON
BOV
AZEV4
AZEVEDO PN
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados